Model* | Coefficient estimate | 95% confidence interval | p-value |
---|---|---|---|
Dependent variable: PR layer thickness at C sector | |||
NP-SLE | − 2.83 | − 5.29 to − 0.37 | 0.025 |
Sjogren’s syndrome | 5.05 | 0.71 to 9.40 | 0.023 |
SLEDAI | − 0.29 | − 0.51 to − 0.06 | 0.015 |
Body mass index (kg/m2) | − 0.31 | − 0.60 to − 0.02 | 0.038 |
Dependent variable: PR layer thickness at S3 sector | |||
Benzodiazepine | 2.67 | 0.35 to 4.99 | 0.025 |
Dependent variable: PR layer thickness at T3 sector | |||
Calcium channel blocker | − 2.68 | − 5.23 to − 0.14 | 0.039 |
Dependent variable: PR layer thickness at I3 sector | |||
Statin | − 1.84 | − 3.48 to − 0.20 | 0.028 |
Dependent variable: PR layer thickness at N3 sector | |||
Sjogren’s syndrome | 2.38 | 0.2 to 4.74 | 0.048 |
SLEDAI | − 0.13 | − 0.26 to 0.00 | 0.050 |
Statin | − 2.44 | − 4.15 to − 0.73 | 0.006 |
Dependent variable: PR layer thickness at S6 sector | |||
Benzodiazepine | 1.95 | 0.23 to 3.68 | 0.027 |
HCQ treatment time (years) | − 0.83 | − 0.16 to 0.00 | 0.041 |
Dependent variable: PR layer thickness at N6 sector | |||
Axial length (mm) | 0.53 | 0.01 to 1.05 | 0.045 |
ACE inhibitor | − 1.50 | − 2.95 to − 0.05 | 0.043 |